ARID1A and breast carcinoma: For example, HDAC inhibition might not be a favorable therapeutic option for ARID1A-mutated ER+ breast cancers, as ARID1A-loss-induced endocrine resistance is mediated by the loss of HDAC1 activity (Nagarajan et al., 2020).